Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0O5QL
|
||||
Former ID |
DIB008921
|
||||
Drug Name |
HT-1067
|
||||
Synonyms |
MOA-B inhibitor (memory impairement) Helicon; MOA-B inhibitor (cognitive disorder/Parkinson's Disease) Helicon
|
||||
Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Discontinued in Phase 1 | [1] | ||
Company |
Dart neuroscience
|
||||
Target and Pathway | |||||
Target(s) | Amine oxidase [flavin-containing] B | Target Info | Inhibitor | [2] | |
BioCyc Pathway | Superpathway of tryptophan utilization | ||||
Tryptophan degradation via tryptamine | |||||
Dopamine degradation | |||||
Putrescine degradation III | |||||
Noradrenaline and adrenaline degradation | |||||
KEGG Pathway | Glycine, serine and threonine metabolism | ||||
Arginine and proline metabolism | |||||
Histidine metabolism | |||||
Tyrosine metabolism | |||||
Phenylalanine metabolism | |||||
Tryptophan metabolism | |||||
Drug metabolism - cytochrome P450 | |||||
Metabolic pathways | |||||
Serotonergic synapse | |||||
Dopaminergic synapse | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
5-Hydroxytryptamine degredation | |||||
Dopamine receptor mediated signaling pathway | |||||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
WikiPathways | Tryptophan metabolism | ||||
Dopamine metabolism | |||||
Phase 1 - Functionalization of compounds | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034020) | ||||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034020) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.